Phase 2, multicenter, randomized, open-label study of TAR-200 in combination with cetrelimab and cetrelimab monotherapy in participants with muscle-invasive urothelial carcinoma of the bladder who are to be treated with radical cystectomy and are ineligible or refuse treatment with platinum-based neoadjuvant chemotherapy (SUNRISE)
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: JANSSEN-CILAG, SA
- Phase: II
- Execution start: 05/05/2022
- End of execution: 28/07/2025
- IP: MIGUEL ARRABAL MARTIN